Summary of EDAP TMS FY Conference Call Company Overview - **Company**: EDAP TMS (NasdaqGM:EDAP) - **Focus**: Global leader in therapeutic ultrasound, specifically for the treatment of cancer and benign diseases, with a strong emphasis on prostate cancer treatment using Focal One technology [2][3] Industry Insights - **Market Opportunity**: - Nearly 1.5 million newly diagnosed prostate cancer cases annually, projected to double to 2.9 million by 2040 [2] - Significant unmet needs in prostate cancer treatment, particularly for patients with intermediate risk [3] Core Product Insights - **Focal One Technology**: - Robotic High-Intensity Focused Ultrasound (HIFU) as a first-line treatment for prostate cancer, addressing a gap between active surveillance and radical treatments [3][4] - Focal One is positioned as a desirable treatment option, already included in guidelines for salvage therapy [4] Clinical Evidence - **Efficacy and Outcomes**: - Focal One demonstrates comparable cancer control to traditional treatments (surgery and radiation) while offering superior functional outcomes, such as preservation of urinary continence and erectile function [10][11] - Landmark studies (HIFI and FARP) show that HIFU has lower complication rates and better functional outcomes compared to surgery [10][11][12] Market Dynamics - **Growth Trends**: - HIFU is experiencing exponential growth, while traditional surgery and radiation therapies are stagnating or declining [6] - The company reported a 52% growth in Focal One installations and a 44% increase in procedures from 2021 to 2025 [19] Reimbursement Landscape - **Payment Mechanisms**: - New Medicare payment mechanisms have increased reimbursement rates for HIFU, making it competitive with traditional surgical payments [12][13] Adoption and Expansion - **Installed Base**: - As of December 31, 2025, 87 Focal One systems installed across 42 academic and 45 community hospitals in the U.S., including top-rated cancer hospitals [13][14] - Growing presence in Europe with 41 systems and 254 treatment sites [16] Future Opportunities - **Additional Markets**: - Potential expansion into treating Benign Prostatic Hyperplasia (BPH) and endometriosis, with significant market sizes identified [16][18] - The U.S. endometriosis market includes 66.5 million diagnosed women, with a focus on providing non-invasive treatment options [18] Competitive Landscape - **Comparison with Other Therapies**: - Discussion on Aquablation therapy for BPH, highlighting concerns about its efficacy and safety compared to HIFU [29][31] Management and Strategy - **Leadership Team**: - Proven management team with experience from leading med tech companies, positioning EDAP for continued growth and innovation in the therapeutic ultrasound market [20] Conclusion - **Outlook**: - EDAP TMS is well-positioned for growth in both men's and women's health markets, with a strong clinical evidence base and favorable reimbursement landscape supporting its innovative HIFU technology [20]